Investors

Press Releases

Date Title View
Toggle Summary Tetraphase Pharmaceuticals to Present at 17th Annual Needham Healthcare Conference
WATERTOWN, Mass. , March 20, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc . (NASDAQ:TTPH) a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate
View HTML
Toggle Summary Tetraphase Pharmaceuticals Reports Fourth Quarter and Full-Year 2017 Financial Results, Highlights Achievements and Key 2018 Milestones
Achieved positive results of Eravacycline in Phase 3 IGNITE 4 clinical trial for cIAI  Filed NDA in US for IV Eravacycline for cIAI and PDUFA date is August 28 th Raised over $65 million through underwritten equity offering  2018 milestones include preparation for commercial launch of Eravacycline
View HTML
Toggle Summary Tetraphase Pharmaceuticals Appoints Larry Edwards Chief Operating Officer
WATERTOWN, Mass. , March 01, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced the promotion of Larry
View HTML
Toggle Summary Tetraphase Pharmaceuticals Announces FDA Acceptance for Filing of its NDA Submission for Eravacycline for the Treatment of Complicated Intra-Abdominal Infections (cIAI)
PDUFA Date Set for August 28, 2018 WATERTOWN, Mass. , Feb. 27, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today
View HTML
Toggle Summary Tetraphase Pharmaceuticals Enters into Exclusive Development and Commercialization Agreement with Everest Medicines for Eravacycline in China
WATERTOWN, Mass. , Feb. 20, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that it has entered into an
View HTML
Toggle Summary Tetraphase Announces Top-Line Results from IGNITE3 Phase 3 Clinical Trial of Eravacycline in Complicated Urinary Tract Infections (cUTI)
̶   Eravacycline Did Not Achieve Co-Primary Endpoints in cUTI Trial   ̶ ̶   Company Continues to Prepare for Commercialization of Eravacycline as a Treatment for cIAI in the U.S. and Europe , Assuming Regulatory Approval    ̶ ̶   Conference Call Scheduled for Today at 4:30 p.m.
View HTML
Toggle Summary Tetraphase Pharmaceuticals Appoints Larry Tsai, M.D. to Chief Medical Officer
WATERTOWN, Mass. , Jan. 02, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced the promotion of Larry Tsai , M.D., Vice
View HTML
Toggle Summary Tetraphase Pharmaceuticals Announces Submission of New Drug Application to FDA for Eravacycline for the Treatment of Complicated Intra-Abdominal Infections (cIAI)
Submission Supported by Positive Data from IGNITE1 and IGNITE4 Clinical Trials WATERTOWN, Mass. , Jan. 02, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant
View HTML
Toggle Summary Tetraphase Pharmaceuticals Added to NASDAQ Biotechnology Index
WATERTOWN, Mass. , Dec. 15, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that it has been selected for addition to the
View HTML
Toggle Summary Tetraphase Pharmaceuticals to Present at BMO Prescriptions for Success in Healthcare Conference 2017
WATERTOWN, Mass. , Dec. 06, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will participate in a
View HTML